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Abstract: Patients with asthma need uninterrupted supplies of affordable, quality-assured essential
medicines. However, access in many low- and middle-income countries (LMICs) is limited. The World
Health Organization (WHO) Non-Communicable Disease (NCD) Global Action Plan 2013–2020 sets
an 80% target for essential NCD medicines’ availability. Poor access is partly due to medicines not
being included on the national Essential Medicines Lists (EML) and/or National Reimbursement
Lists (NRL) which guide the provision of free/subsidised medicines. We aimed to determine how
many countries have essential asthma medicines on their EML and NRL, which essential asthma
medicines, and whether surveys might monitor progress. A cross-sectional survey in 2013–2015 of
Global Asthma Network principal investigators generated 111/120 (93%) responses—41 high-income
countries and territories (HICs); 70 LMICs. Patients in HICs with NRL are best served (91% HICs
included ICS (inhaled corticosteroids) and salbutamol). Patients in the 24 (34%) LMICs with no
NRL and the 14 (30%) LMICs with an NRL, however no ICS are likely to have very poor access to
affordable, quality-assured ICS. Many LMICs do not have essential asthma medicines on their EML
or NRL. Technical guidance and advocacy for policy change is required. Improving access to these
medicines will improve the health system’s capacity to address NCDs.
Keywords: essential medicines; access; noncommunicable diseases; asthma; inhaled corticosteroids;
bronchodilators; national reimbursement list
1. Introduction
Asthma, one of the major chronic diseases, has become a cause for global concern due to its
increasing prevalence, morbidity, and economic impact. The Global Burden of Disease study estimated
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that there are 339 million people with asthma globally [1]. In 2016, it ranked 16th in the global causes
of years lived with disability [2]. Since asthma is more prevalent among younger working age groups,
it also has a major economic impact due to loss of productivity [3].
Patients with a chronic condition such as asthma need access to an uninterrupted supply of
appropriate, effective, quality-assured essential medicines which need to be affordable for patients
over the long term. However, studies continue to indicate a lack of availability and affordability
of asthma essential medicines, especially in low- and middle-income countries (LMICs), and draw
attention to medicine-related barriers to effective asthma management [4–10]. Serious concerns persist
about the weakness of pharmaceutical quality assurance and of the capacity among national regulatory
authorities in these countries [11].
Following the United Nations High Level Meeting on Noncommunicable Diseases (NCDs) in
2011, the World Health Organization developed a Global Action Plan for the Prevention and Control of
Noncommunicable Diseases 2013–2020 (GAP) [12]. The GAP includes a number of voluntary targets,
one of which relates to improving access to essential medicines. Countries are to achieve “an 80%
availability of the affordable basic technologies and essential medicines, including generics, required
to treat major NCDs in both public and private facilities” [12]. In many countries, access to NCD
medicines is well below this target [13]. Calls have been made to implement systematic monitoring of
progress in improving access to NCD medicines [14], including the tracking of national targets and
indicators [15].
The World Health Organization (WHO) defines essential medicines as those that satisfy the
priority health care needs of the population. Such medicines are intended to be available within the
context of functioning health systems at all times in adequate amounts, in the appropriate dosage
forms, with assured quality, and at a price that the individual and the community can afford. WHO
promotes the concept of a national Essential Medicines List (EML), which is a government-approved
selective list of medicines which guides the procurement and supply of medicines in the public sector,
schemes that reimburse medicine costs, medicine donations, and local medicine production. When
properly resourced, an EML is a cost-effective means of providing safe, effective treatment for the
majority of high burden diseases [16]. However, availability is only part of the solution; affordability
is also crucial. Cost to consumers is driven by the market price and the availability of subsidies or
reimbursement. Where reimbursement is available, it is important that effective treatments for high
burden diseases are included on the list of reimbursed medications. Thus, there are two national-level
lists that countries can use to facilitate access to appropriate and affordable medicines: a national EML
and a national reimbursement list (NRL).
For asthma, the 2013 version of the WHO EML, current at the time of the survey, included two
types of inhaled corticosteroids (ICS): beclometasone 50 micrograms (µg) and 100 µg, and budesonide
100 µg and 200 µg, as well as one inhaled bronchodilator: salbutamol 100 µg as the medicines that
are generally available at the lowest price, based on international drug price information sources [17].
These off-patent medicines are also included in the three global guidelines and manuals about asthma
management, which all acknowledge the importance of prioritising cost-effective essential medicines
for primary health care [18–20] and are still in the current WHO EML [21]. Since people with persistent
asthma require long term treatment with both ICS and bronchodilator aerosols, EMLs should include
items from both of these classes.
However, it is not clear how many countries include and/or update the essential asthma medicines
on their EML and how many have asthma medicines on an NRL so that these medicines can be
provided free or at subsidised prices to populations, especially the poor and vulnerable. Thus,
the Global Asthma Network (GAN) undertook a survey to determine (a) how many countries have
the essential asthma medicines on their EML and/or NRL, (b) which essential asthma medicines they
include, and (c) whether surveys of an international network might help to monitor progress.
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2. Methods
A cross-sectional email survey was conducted between 2013 and 2015. The questionnaire and
cover letter were emailed by the GAN Global Centre (Auckland) to the principal investigator of each
of 276 GAN centres in 120 countries and territories, including 41 high-income countries and territories
(HICs) and 79 LMICs. Three French overseas territories were included as HICs since they have always
been presented as distinct centres for asthma prevalence surveys that have been undertaken by the
International Study on Asthma and Allergies in Childhood (ISAAC) [22] and GAN.
The survey asked two main questions. Respondents were asked whether their country’s EML
and NRL contained each of three WHO EML asthma medicines in dosages listed in the WHO EML
(beclometasone 50 µg and 100 µg, and budesonide 100 µg and 200 µg, and salbutamol 100 µg). If they
knew their country had no such list, they were to write “Not applicable”. Otherwise, they were to
write “Yes”, “No” or “Don’t know”.
Data were entered into an Excel spreadsheet. Questionnaire responses were checked and any
unclear answers were queried with the respondents. Where multiple questionnaires with different
answers were returned for the same country, the GAN Global Centre staff discussed via email with
one or more of the principal investigators to determine the appropriate answer.
Countries were analysed in two categories: high-income and low- and middle-income, in
accordance with World Bank classification 2014 [23]. Medicines were analysed as separate items
(5), however the ICS were also analysed as the group “Any ICS” (4). Basic descriptive analysis
was performed.
Ethics approval was not sought as this survey collects data that are routinely available and does
not use any personal data. Principal investigators are mainly respiratory specialists who work in major
health facilities in their country. Participation in GAN research is voluntary and is not remunerated.
3. Results
Data were returned for 111 (41 HICs and 70 LMICs) of 120 countries that were surveyed (93%
response rate). Results for each country are presented in Tables 1–4, with countries grouped as HICs
(Tables 1 and 3) and LMICs (Tables 2 and 4). Table 5 provides a summary of the data.
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Table 1. Existence of National Medicine List and National Reimbursement List and inclusion of any
inhaled corticosteroid and salbutamol, 41 high-income countries and territories, 2014 *.
High-Income
Countries and
Territories
Have EML Any ICS on EML S on EML Have NRL Any ICS on NRL S on NRL
Australia N n/a n/a Y Y Y
Austria N n/a n/a Y Y Y
Belgium Y N Y Y Y Y
Canada Y Y Y Y Y Y
Channel Islands Y Y Y Y Y Y
Chile Y Y Y Y Y Y
Croatia Y Y Y Y Y Y
Cyprus N n/a n/a Y Y Y
Denmark Y Y N Y N N
Faroe Islands Y Y Y Y Y Y
Finland N n/a n/a Y Y Y
France N n/a n/a Y Y Y
French Polynesia N n/a n/a Y Y Y
Germany N n/a n/a Y Y Y
Hong Kong N n/a n/a Y Y Y
Ireland N n/a n/a Y Y Y
Israel Y Y N Y Y N
Italy Y Y Y Y Y Y
Japan N n/a n/a Y Y Y
Korea, South Y Y Y N n/a n/a
Kuwait Y Y Y Y Y Y
Latvia Y N Y Y N Y
Malta N n/a n/a Y Y Y
Netherlands N n/a n/a Y Y Y
New Caledonia N n/a n/a Y Y Y
New Zealand N n/a n/a Y Y Y
Norway N n/a n/a Y Y Y
Oman Y Y Y N n/a n/a
Poland Y Y Y Y Y Y
Portugal Y N N Y Y Y
Reunion Island N n/a n/a Y Y Y
Russia Y Y Y Y Y Y
Saudi Arabia Y Y Y N n/a n/a
Singapore Y Y Y Y Y Y
Spain N n/a n/a Y Y Y
Trinidad and Tobago Y Y Y Y Y Y
United Arab Emirates Y Y Y Y Y Y
United Kingdom Y Y Y Y Y Y
United States N n/a n/a N n/a n/a
Uruguay Y N Y N n/a n/a
Vatican City N n/a n/a N n/a n/a
Total Y/total HICs (41) 22 35
Total Y/total HICs with
EML (22) 18 19
Total Y/total HICs with
NRL (35) 33 33
Total as % 54 82 86 85 94 94
* N: No; n/a: not applicable; Y: Yes. Where a list does not exist, medicine data are marked as n/a. EML:
Essential Medicine List; ICS: Inhaled corticosteroid; HICs: High-income countries and territories; NRL: National
Reimbursement List; S: Salbutamol.
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Table 2. Existence of National Medicine List and National Reimbursement List and inclusion of any
inhaled corticosteroid and salbutamol, 70 low- and middle-income countries, 2014 *.
Low- and Middle-Income Countries Have EML Any ICS onEML S on EML Have NRL
Any ICS on
NRL S on NRL
Albania Y Y Y Y Y Y
Algeria Y Y Y Y Y Y
Argentina Y N N Y Y Y
Armenia Y N Y Y N Y
Belarus Y Y Y Y Y Y
Benin Y N N N n/a n/a
Bolivia Y Y Y Y N Y
Bosnia and Herzegovina Y N Y Y N Y
Brasil Y Y Y Y N N
Bulgaria Y Y Y Y Y Y
Burkina Faso Y Y Y Y N N
Cameroon Y N N N n/a n/a
China Y Y Y Y Y Y
Colombia Y Y Y N n/a n/a
Congo Dem Rep Y Y Y N n/a n/a
Costa Rica Y Y Y Y Y Y
Ecuador Y Y Y Y Y Y
Egypt Y N N Y N N
El Salvador Y Y Y Y Y Y
Fiji Y Y Y Y Y N
Gambia Y N N N n/a n/a
Georgia Y N N N n/a n/a
Ghana Y Y Y Y Y Y
Grenada Y Y Y N n/a n/a
Hungary Y Y Y Y Y Y
India Y Y Y Y Y Y
Indonesia Y Y Y Y N Y
Iran Y Y Y Y Y Y
Jamaica Y Y Y Y Y Y
Jordan Y Y Y Y Y Y
Kenya Y N N N n/a n/a
Kosovo Y N Y Y N N
Lao PDR Y N Y Y N N
Macedonia Y Y Y Y Y Y
Malawi Y Y Y N n/a n/a
Malaysia Y Y Y N n/a n/a
Mexico Y Y Y Y Y Y
Mongolia Y Y Y Y N Y
Nicaragua Y Y Y Y Y Y
Nigeria Y Y Y N n/a n/a
Niue Y Y Y N n/a n/a
Pakistan Y N N N n/a n/a
Palau Y Y Y N n/a n/a
Palestine Y Y Y N n/a n/a
Panama Y Y Y Y Y Y
Peru Y Y Y Y Y Y
Philippines Y Y Y Y Y Y
Romania Y Y Y Y Y Y
Samoa Y Y Y Y N N
Senegal Y N N Y N N
Serbia Y Y Y Y Y Y
Sierra Leone Y Y Y N n/a n/a
South Africa Y Y Y Y Y Y
Sri Lanka Y Y Y N n/a n/a
Sudan Y Y Y Y Y Y
Syrian Arab Republic Y N Y Y Y Y
Taiwan N n/a n/a Y Y Y
Thailand Y Y Y Y Y Y
Togo Y Y Y Y Y Y
Tokelau Y Y Y N n/a n/a
Tonga Y Y Y N n/a n/a
Tunisia Y Y Y Y Y Y
Turkey N n/a n/a Y Y Y
Tuvalu Y Y Y N n/a n/a
Uganda Y Y Y N n/a n/a
Ukraine Y Y Y Y N N
Vanuatu Y Y Y N n/a n/a
Vietnam Y N Y Y N Y
Zambia Y Y Y N n/a n/a
Zimbabwe Y Y Y N n/a n/a
Total Y/total LMICs (70) 68 46
Total Y/total LMICs with EML (68) 53 59
Total Y/total LMICs with NRL (46) 32 37
Total as % 97 78 87 66 70 80
* N: No; n/a: not applicable; Y: Yes. Where a list does not exist, medicine data are marked as n/a. EML:
Essential Medicine List; ICS: Inhaled Corticosteroid; LMICs: Low- and middle-income countries; NRL: National
Reimbursement List; S: Salbutamol.
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Table 3. Inclusion of HFA inhalers from the WHO Essential Medicines List in National Essential
Medicine and National Reimbursement Lists in 41 high-income countries and territories, 2014 *.
High-Income
Countries and
Territories
Beclometasone
50 µg
Beclometasone
100 µg
Budesonide
100 µg
Budesonide
200 µg
Salbutamol
100 µg
EML NRL EML NRL EML NRL EML NRL EML NRL
Australia n/a Y n/a Y n/a N n/a N n/a Y
Austria n/a Y n/a Y n/a Y n/a Y n/a Y
Belgium N Y N N N N N Y Y Y
Canada Y Y Y Y N N N N Y Y
Channel Islands Y Y Y Y Y Y Y Y Y Y
Chile Y Y Y Y Y Y Y Y Y Y
Croatia Y Y Y Y N N N N Y Y
Cyprus n/a N n/a Y n/a N n/a N n/a Y
Denmark N N Y N N N Y N N N
Faroe Islands Y Y Y Y Y Y Y Y Y Y
Finland n/a Y n/a Y n/a N n/a N n/a Y
France n/a Y n/a Y n/a Y n/a Y n/a Y
French Polynesia n/a Y n/a Y n/a Y n/a Y n/a Y
Germany n/a Y n/a Y n/a Y n/a Y n/a Y
Hong Kong n/a Y n/a Y n/a Y n/a Y n/a Y
Ireland n/a Y n/a Y n/a N n/a N n/a Y
Israel Y Y Y Y Y Y Y Y N N
Italy Y Y Y Y Y Y Y Y Y Y
Japan n/a Y n/a Y n/a Y n/a Y n/a Y
Korea, South Y n/a Y n/a Y n/a Y n/a Y n/a
Kuwait Y Y Y Y Y Y Y Y Y Y
Latvia N N N N N N N N Y Y
Malta n/a Y n/a N n/a N n/a Y n/a Y
Netherlands n/a Y n/a Y n/a Y n/a Y n/a Y
New Caledonia n/a Y n/a Y n/a Y n/a Y n/a Y
New Zealand n/a Y n/a Y n/a N n/a N n/a Y
Norway n/a Y n/a Y n/a N n/a N n/a Y
Oman Y n/a Y n/a N n/a N n/a Y n/a
Poland N N Y Y N N Y Y Y Y
Portugal N Y N Y N Y N Y N Y
Reunion Island n/a Y n/a Y n/a Y n/a Y n/a Y
Russia Y Y Y Y N N N N Y Y
Saudi Arabia Y n/a N n/a N n/a Y n/a Y n/a
Singapore Y Y N N N N N N Y Y
Spain n/a Y n/a N n/a Y n/a Y n/a Y
Trinidad and Tobago Y Y Y Y Y N Y N Y Y
United Arab Emirates N N Y Y Y Y Y Y Y Y
United Kingdom Y Y Y Y N N N N Y Y
United States n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Uruguay N n/a N n/a N n/a N n/a Y n/a
Vatican City n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Total Y/total HICs
with EML (22) 15 16 9 12 19
Total Y/total HICs
with NRL (35) 30 29 18 21 33
Total as % 68 86 73 83 41 51 55 60 86 94
* N: No; n/a: not applicable; Y: Yes. Where a list does not exist, medicine data are marked as n/a. WHO: The World
Health Organization; EML: Essential Medicine List; HFA: hydrofluoroalkane; HICs: High-income countries and
territories; NRL: National Reimbursement List.
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Table 4. Inclusion of HFA inhalers from the WHO Essential Medicines List in National Essential
Medicine and National Reimbursement Lists in 70 low- and middle-income countries, 2014 *.
Low- and
Middle-Income
Countries
Beclometasone
50 µg
Beclometasone
100 µg
Budesonide
100 µg
Budesonide
200 µg
Salbutamol
100 µg
EML NRL EML NRL EML NRL EML NRL EML NRL
Albania Y Y Y Y Y Y Y Y Y Y
Algeria N N N N Y Y Y Y Y Y
Argentina N N N N N Y N Y N Y
Armenia N N N N N N N N Y Y
Belarus Y Y Y Y Y Y Y Y Y Y
Benin N n/a N n/a N n/a N n/a N n/a
Bolivia Y N Y N Y N Y N Y Y
Bosnia and Herzegovina N N N N N N N N Y Y
Brasil Y N N N N N N N Y N
Bulgaria Y Y Y Y Y Y Y Y Y Y
Burkina Faso Y N N N N N Y N Y N
Cameroon N n/a N n/a N n/a N n/a N n/a
China Y Y N N N N N N Y Y
Colombia Y n/a N n/a N n/a N n/a Y n/a
Congo Dem Rep N n/a Y n/a N n/a N n/a Y n/a
Costa Rica N N Y Y N N N N Y Y
Ecuador Y Y Y Y N N N N Y Y
Egypt N N N N N N N N N N
El Salvador Y Y N N N N N N Y Y
Fiji N N Y Y N N N N Y N
Gambia N n/a N n/a N n/a N n/a N n/a
Georgia N n/a N n/a N n/a N n/a N n/a
Ghana N N Y Y Y Y Y Y Y Y
Grenada Y n/a Y n/a N n/a N n/a Y n/a
Hungary N N N N Y Y Y Y Y Y
India Y Y Y Y Y Y Y Y Y Y
Indonesia N N N N Y N Y N Y Y
Iran Y Y N N Y Y Y Y Y Y
Jamaica Y Y Y Y N N Y Y Y Y
Jordan Y Y Y Y N N N N Y Y
Kenya N n/a N n/a N n/a N n/a N n/a
Kosovo N N N N N N N N Y N
Lao PDR N N N N N N N N Y N
Macedonia Y Y N N N N Y Y Y Y
Malawi Y n/a Y n/a N n/a N n/a Y n/a
Malaysia N n/a Y n/a Y n/a Y n/a Y n/a
Mexico N Y N Y Y Y Y Y Y Y
Mongolia Y N Y N N N N N Y Y
Nicaragua Y Y Y Y N N N N Y Y
Nigeria Y n/a N n/a N n/a N n/a Y n/a
Niue N n/a Y n/a N n/a N n/a Y n/a
Pakistan N n/a N n/a N n/a N n/a N n/a
Palau N n/a Y n/a N n/a N n/a Y n/a
Palestine N n/a N n/a N n/a Y n/a Y n/a
Panama Y Y N N N N Y Y Y Y
Peru Y Y N N N N Y Y Y Y
Philippines Y Y Y Y N N Y Y Y Y
Romania Y Y Y Y Y Y Y Y Y Y
Samoa N N Y N N N N N Y N
Senegal N N N N N N N N N N
Serbia Y N Y Y Y N Y Y Y Y
Sierra Leone Y n/a Y n/a N n/a N n/a Y n/a
South Africa Y Y Y Y Y Y Y Y Y Y
Sri Lanka Y n/a Y n/a N n/a N n/a Y n/a
Sudan Y N N N N N N Y Y Y
Syrian Arab Republic N Y N Y N Y N Y Y Y
Taiwan n/a N n/a N n/a N n/a Y n/a Y
Thailand Y Y Y Y Y Y Y Y Y Y
Togo Y Y Y Y N N N N Y Y
Tokelau Y n/a N n/a N n/a N n/a Y n/a
Tonga N n/a Y n/a N n/a N n/a Y n/a
Tunisia Y Y N N N N N Y Y Y
Turkey n/a Y n/a Y n/a Y n/a Y n/a Y
Tuvalu Y n/a Y n/a N n/a N n/a Y n/a
Uganda Y n/a N n/a N n/a N n/a Y n/a
Ukraine N N N N Y N Y N Y N
Vanuatu Y n/a N n/a N n/a N n/a Y n/a
Vietnam N N N N N N N N Y Y
Zambia Y n/a N n/a N n/a N n/a Y n/a
Zimbabwe Y n/a Y n/a N n/a N n/a Y n/a
Total Y/total LMICs
with EML (68) 38 31 17 24 59
Total Y/total LMICs
with NRL (46) 23 20 15 24 37
Total as % 56 50 46 43 25 33 35 52 87 80
* N: No; n/a: not applicable; Y: Yes. Where a list does not exist, medicine data are marked as n/a. EML:
Essential Medicine List; HFA: hydrofluoroalkane; LMICs: Low- and middle-income countries; NRL: National
Reimbursement List.
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Table 5. Existence of an Essential Medicine List and National Reimbursement List, and inclusion.
High-Income
Countries and
Territories (41)
N (%)
Low- and
Middle-Income
Countries (70)
N (%)
Total N (%) p-Value *
Essential Medicines List (EML)
Have EML 22 (54) 68 (97) 90 (81) <0.001
Any inhaled
corticosteroid (ICS) 18 (82) 53 (78) 71 (79) 0.7
Salbutamol 19 (86) 59 (87) 78 (87) 0.9
Beclometasone 50 µg 15 (68) 38 (56) 53 (59) 0.3
Beclometasone 100 µg 16 (73) 31 (46) 47 (52) 0.03
Budesonide 100 µg 9 (41) 17 (25) 26 (29) 0.2
Budesonide 200 µg 12 (55) 24 (35) 36 (40) 0.1
National Reimbursement List (NRL)
Have NRL 35 (85) 46 (66) 81 (73) 0.02
Any ICS 33 (94) 32 (70) 65 (80) 0.006
Salbutamol 33 (94) 37 (80) 70 (86) 0.07
Beclometasone 50 µg 30 (86) 23 (50) 53 (65) <0.001
Beclometasone 100 µg 29 (83) 20 (43) 49 (60) <0.001
Budesonide 100 µg 18 (51) 15 (33) 33 (41) 0.9
Budesonide 200 µg 21 (60) 24 (52) 45 (56) 0.5
Any ICS and
Salbutamol 32 (91) 31 (67) 63 (78) 0.01
* p Value difference in proportion between high-income countries and territories and low- and
middle-income countries.
3.1. Essential Medicine Lists
Of the 111 responding countries, 90 (81%) had an EML. A higher percentage of LMICs reported
having an EML: 68 (97%) LMICs versus 22 (54%) HICs. However, of the 90 countries with an EML,
only 71 (79%) included one or more inhaled corticosteroid. This included 18 (82%) HICs and 53 (78%)
LICs. The proportion of all countries that included salbutamol on their EML was higher (87%) than
the proportion that included any ICS (79%).
3.2. National Reimbursement Lists
Fewer countries had an NRL than an EML (73% versus 81%). Of the 81 (73%) countries that
reported having an NRL, 65 (80%) had one or more ICS on the NRL. There was a marked difference
between country income level regarding inclusion of one or more ICS on the NRL: 33 (94%) HICs versus
32 (70%) LMICs. Regarding dosages for each ICS, the income differences persisted: beclometasone
50 µg was included by 30 (86%) HICs versus 23 (50%) LMICs; beclometasone 100 µg was included by
29 (83%) HICs versus 20 (43%) LMICs. Only 16 (35%) LMICs had both dosages of beclometasone on
their NRL versus 26 (74%) HICs. Best reimbursed was salbutamol: 70 (86%) countries included it; 94%
of HICs and 80% of LMICs.
A large difference between country income groups was observed for the inclusion of any ICS and
salbutamol on the NRL: 32 (91%) HICs and 31 (67%) LMICs with a p value of 0.01.
4. Discussion
This survey shows that many countries do not have all the WHO-recommended essential asthma
medicines at the recommended dosages on their EML. Many country representatives also report that
the medicines are not included in any type of NRL, which probably indicates that the medicines are
not being provided free or subsidised for patients.
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The concepts of essential medicines, of access to essential medicines as a human right,
and universal coverage are relevant for all countries, regardless of income [14,24,25]. The national
EML, a concept launched in 1977, has retained an important role in creating and maintaining access
to medicines over the years [26]. In 2015, Sustainable Development Goal 3.8 was created with a
target to achieve “access to safe, effective, quality and affordable essential medicines and vaccines
for all” [27]. The WHO includes the EML as a key component of a well-functioning health system,
noting that it is to guide procurement, reimbursement, and training [28]. It calls it “a guide for national
committees that are responsible for identification of the most cost-effective medicines at country level
for procurement, reimbursement, and treatment decisions, and helps to focus national efforts towards
universal coverage”. Although the nature of the EML may be expanding slightly to incorporate
recently released medicines that are still expensive, this does not contradict the basic principle of
prioritising medicines from a clinical and public health perspective, and aiming to achieve access for
all, especially the poor and vulnerable [29]. Getting medicines on the EML is still viewed as a first
step towards access [29]. The WHO Director-General recently commented on access to new medicines:
“[p]lacing them on the WHO Essential Medicines List is a first step in that direction” [30].
Health systems are dynamic, complex systems with barriers that can occur at multiple levels and
be interrelated [31]. A lack of prioritisation of asthma medicines in national level documents, such as
EMLs and NRLs, is likely to create policy- and supply-related barriers to access that, in turn, impact
many levels and many other processes in the health system. With a cumulative effect, these barriers
are likely to have a detrimental effect on patient pathways, access, and adherence to treatment.
The survey identified some major gaps in LMICs regarding the existence of national lists and
the inclusion of medicines. Although LMICs had higher percentages than HICs for the existence of
an EML and the inclusion of salbutamol on the EML, they had consistently lower percentages for all
other questions.
The results relating to inclusion of ICS on national lists in LMICs are of particular concern. Firstly,
22% of LMICs with an EML still do not include any ICS, and 14 (30%) of those with an NRL do not
include any ICS. In addition, it is likely that the 24 (34%) LMICs that reported not having an NRL are
unlikely to have any other way of making ICS affordable for patients. Thus, patients are likely to find
ICS unaffordable in 38 (54%) of the total LMICs surveyed.
Secondly, ICS, the preventer medicines that lead to improved asthma control, are less commonly
reimbursed by LMIC governments than salbutamol, the short-term reliever inhaler that does not
reduce the burden of asthma in the long term if applied without an ICS. This may reflect an ongoing
misunderstanding among some policy-makers, specialist physicians, and other health workers about
the importance of ICS in the long-term management of asthma. The lack of prioritisation of ICS in
national level lists is likely to be playing a role in the underprescription and underuse of ICS which
continues to be reported [32–34].
Thirdly, few LMICs have both dosages of beclometasone or budesonide. Yet, a range of doses of
ICS is needed so that the appropriate and convenient dosage can be prescribed for each level of disease
severity and for children as well as adults. Patient outcomes and adherence may be unfavourably
affected by this constraint.
Most results for most HICs appear favourable, however they should be interpreted with some
caution. Patients in the 91% of HICs reporting an NRL that include both ICS and salbutamol may have
good access to the complete treatment that is required for their asthma. However, it would be incorrect
to assume that including asthma medicines on an EML or an NRL means that they are in practice
affordable and available for all groups of their populations [35]. Access for low-income and vulnerable
populations in HICs may in fact be as poor as in some LMICs. A study in Denmark found that high
levels of socio-economic status were positively associated with high use of ICS and concluded that
attention should be paid to asthma sufferers with low educational level and low income [36].
In our survey, 18 HICs reported not having an EML, seven reported no NRL, and two reported
having neither. It is a country level decision whether to formulate such national lists or not. However, if
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there are no national documents to guide decision-making, there is a risk that governments might lose
sight of the principles behind essential medicines. A qualitative stakeholder analysis that interviewed
medicine decision-makers in Australia found much variety in definitions and understanding about
the concept of essential medicines and its application with regard to reimbursement decisions [37].
Researchers and practitioners in Canada have developed a preliminary list of essential medicines for
primary care, in line with parliamentary recommendations and a concern that suboptimal prescribing
might be partially related to the large number of medicines that are available [38,39].
There may be a number of reasons why countries have not included the recommended asthma
medicines or dosages. Some EMLs and NRLs may not have been updated recently or since
the changeover from chlorofluorocarbon-propelled inhalers, which saw the dosages change for
beclometasone. It may be that there are no national asthma guidelines, meaning that individual
specialists and health services select medicines unguided; a low priority for asthma and chronic
respiratory diseases in general [40,41]; or strong undue influence on the EML selection process
due to pharmaceutical or trade-related lobbying. It may be that countries have other dosages or
formulations of these medicines, or other asthma medicines in circulation. Other medicines are likely
to be considerably more expensive and thus less accessible, especially for poorer populations.
A number of major limitations should be noted. The survey relied on self-reported data sent
by a single individual. It is possible that principal investigators might have incorrectly interpreted
information about their national lists. Within the scope of this unfunded survey, however, it would
have been impractical for GAN to request copies of EMLs and lists of reimbursed medicines in an
attempt to validate responses. In addition to time and cost considerations, country lists are written in
the language of the country and are complex to interpret without knowledge of each country’s health
system. Since the principal investigators are researchers and practitioners who are familiar with the
medicines involved, we believed that the risk of respondent error would been low.
A further limitation is that the survey did not explore any health systems’ details about the
context, nature, or date of the latest update of the EMLs or NRLs. It is likely to have been difficult
for some countries, especially federal and decentralised systems, to answer about the existence of a
national reimbursement list or similar. Some respondents asked for clarification of our definition of
NRL, however might have felt their answer was not representative of their country’s health system.
Thus, the results may be misrepresenting the policy situation in some countries and they should be
viewed with some caution. Future surveys could develop the questions about reimbursed and free
medicines, expand guidance and explanations, and include a method for validating responses.
The survey has several strengths. It was an inexpensive, rapid way to gain a snapshot of the
inclusion on national level lists of essential asthma medicines in a large number of countries (111) from
all WHO regions, including a large number of LMICs (70). The response rate of 93% was high for a
survey, perhaps reflecting the longstanding collaboration between many principal investigators and
those involved in GAN, the conciseness of the survey, and the importance accorded to the topic of
access to essential medicines by principal investigators.
The survey highlights areas for action. Firstly, the monitoring of progress towards NCD medicine
availability targets is important as it can identify gaps. Roles and resources for monitoring should be
allocated at sub-national, national, and global levels so that various entities can contribute to improving
medicine availability. We support calls for systematic monitoring of progress that is built into national
routine information systems and includes policy and health systems indicators [42,43]. Alongside
efforts to set up these important national systems, which may take some time, surveys could also be
undertaken by global networks, such as GAN, comprised of committed health professionals who are
used to applying standardised protocols [44] and the Global Alliance for Chronic Respiratory Disease.
At a minimum, there should be regular surveys of availability, pricing, and affordability in public
and private health facilities of the essential asthma medicines, for example, following the WHO-HAI
methodology [45]. Spacers, which enable a subset of patients, in particular children, to use ICS inhalers
effectively, could be included.
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Secondly, some countries may want to update their lists and work out whether their other national
level policies, strategies, and procedures are aligned to facilitate access to asthma essential medicines.
The Lancet Commission on Essential Medicines Policies has provided a comprehensive series of
actionable recommendations related to financing, affordability, quality and safety, quality use of
medicines, developing missing medicines, and measuring progress [43]. These should help countries
to take concrete steps towards achieving the 80% NCD medicine availability target [12] and Sustainable
Development Goal target 3.8 [27]. Human and financial resources will need to be allocated for the
necessary technical and policy work. International entities that promote access to essential medicines
should see how they can assist where requested.
Thirdly, this survey should stimulate enquiry about the transparency of the medicine selection
process at the national level and why ICS, in particular, are still missing from so many EMLs and NRLs.
Attention should be drawn to the fact that undue influence over the selection processes may stem
from conflicts of interests from governments, donor organisations, pharmaceutical companies, among
other entities. We recommend advocating for national level medicines lists and policies that will
promote evidence-based decision-making. Communities could take a rights-based approach to access
to essential medicines and track progress towards the 80% availability target, holding governments
accountable for gaps in access to NCD medicines, such as those for asthma [14]. We encourage all
governments to reflect the principles of essential medicines and universal coverage in their medicines
and reimbursement lists.
5. Conclusions
Many countries do not have the WHO-recommended essential asthma medicines on their national
level medicine lists, and many are not providing the medicines free or subsidised for patients, especially
in LMICs. This situation creates barriers for patient access to medicines and is likely to be perpetuating
the underprescription and underuse of ICSs. One step towards the WHO 80% availability target for
NCD essential medicines will be for countries to ensure that asthma essential medicines feature on
their national medicines lists, with the correct dosages. Our survey obtained a very high response
rate. With a strengthened methodology, international surveys could be one way to monitor progress
towards the inclusion of essential asthma medicines on national level medicine lists. Progress should
be monitored and evaluated at the national and international level. As part of the broader efforts to
strengthen health systems, these policy-related measures are crucial first steps towards making these
essential medicines available, quality-assured, and affordable for all.
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